Chronic cutaneous adverse events affected 8% of patients after checkpoint inhibitor therapy in a cohort study, often ...

In patients with advanced melanoma, nivolumab/relatlimab combination therapy shows a cutaneous irAEs prevalence of 21.5%, ...

David Zhen, MD, discussed the relevance of nivolumab in the upper gastrointestinal cancer population. In an interview with ...

The Phase II trial examined the therapeutic cancer vaccine Tedopi in combination with chemotherapy drug combination FOLFIRI.

Ono Pharmaceuticals has secured the global rights to sapablursen, an RNA-targeting therapy by Ionis to treat polycythemia ...

Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...

Updated results from the CheckMate 274 trial provide support for adjuvant nivolumab as a standard of care for muscle-invasive bladder cancer, according to Matthew Milowsky, MD.

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

Phase 2 trial results support further development of neoadjuvant nivolumab-based CIT and adaptive de-escalation of CRT in patients with locoregionally advanced HNSCC, according to researchers.

Updated clinical & translational results: BOND-003 Cohort C- A phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for high-risk BCG-unresponsive non-muscle invasive bladder ...

The FDA has accepted the sBLA for nivolumab (Opdivo) plus ipilimumab (Yervoy) as a potential first-line treatment for advanced MSI-H or dMMR CRC.

Combination treatment with nivolumab and cabozantinib provides long-term benefits over sunitinib in patients with advanced RCC, according to final results from the CheckMate 9ER trial.